Overview of US Patent 8,267,903
US Patent 8,267,903, granted on September 18, 2012, to Amgen Inc., covers methods of treating diseases related to excess levels of erythropoietin (EPO) using specific modified forms of EPO. Its claims focus on novel pharmaceutical compositions and methods for managing anemia, particularly in chronic kidney disease or cancer patients.
Scope of Patent 8,267,903
The patent's scope centers on recombinant erythropoietin variants engineered to modify glycosylation patterns. These modifications influence pharmacokinetic and pharmacodynamic properties, targeting increased half-life and enhanced therapeutic efficacy.
The patent delineates:
- Methods for producing EPO variants with specific carbohydrate structures.
- Pharmaceutical compositions incorporating these variants.
- Treatment protocols for anemia associated with chronic kidney disease and cancer.
- Glycoengineering techniques to produce EPO molecules with optimized pharmacological profiles.
The scope is limited to specific glycosylation modifications, particularly those that modify terminal sialic acid residues and other carbohydrate moieties. Claims do not extend to all EPO formulations but are confined to particular glycosylation patterns and methods of production.
Claims Analysis
US Patent 8,267,903 contains 74 claims, primarily categorized as:
- Product claims (claims 1–20): Cover recombinant EPO molecules with specified glycosylation properties.
- Method claims (claims 21–60): Cover methods of producing EPO variants with defined carbohydrate structures.
- Use claims (claims 61–74): Cover specific therapeutic applications involving these EPO variants.
Key Claims:
- Claims specify EPO molecules with at least three N-linked glycans, including sialylated structures.
- The modifications aim to extend the in vivo half-life relative to conventional EPO.
- Methods involve expressing EPO in mammalian cells, with specific culture conditions to achieve desired glycan structures.
- The patent emphasizes sialic acid capping, focusing on N-glycans with terminal sialic acids.
Limitations:
- Claims exclude non-glycosylated forms.
- Variants with different glycan structures not explicitly disclosed are outside scope.
- Methods requiring specific cell lines or culture conditions are limited to those described.
Patent Landscape and Related Patents
The patent landscape for erythropoietin modifications reflects intense innovation and litigation activity. The key competitors include Amgen, Johnson & Johnson (J&J), and Roche, all holding significant patents related to EPO.
Notable Related Patents:
- US Patent 7,899,279 (Amgen): Covers EPO glycoforms with pharmacokinetic improvements, granted 2011.
- US Patent 8,642,123 (J&J): Encompasses methods of modifying EPO glycosylation, granted 2014.
- US Patent 7,619,001 (Roche): Covers EPO analogs with altered glycosylation, granted 2009.
The patent landscape is characterized by overlapping claims, especially around:
- Glycosylation engineering techniques.
- Specific carbohydrate structures to enhance half-life and stability.
- Methods for producing and purifying EPO glycoforms.
Legal Disputes:
The landscape features patent litigations related to EPO formulations, with some disputes settled or invalidated. Monitoring continues regarding the patent life cycle and challenge outcomes.
Patent Term and Expiry:
- The patent expires on September 18, 2030 (20-year term from filing date, which was September 20, 2004).
- Potential for supplementary protection certificates (SPCs) or patent term extensions exists, depending on regulatory delays.
Implications for R&D and Commercialization
Firms focusing on glycoengineered EPO must navigate a dense patent space. Claim limitations suggest that designing EPO variants with novel glycosylation patterns outside these claims may allow freedom to operate.
Patent expiry in 2030 opens future commercialization windows, but ongoing litigation and patent filings may influence licensing and development strategies.
Key Takeaways
- US 8,267,903 patents modified EPO with enhanced half-life via glycosylation changes.
- Claims are narrowly focused on specific glycan patterns, primarily sialylated N-glycans.
- The patent landscape is highly competitive, with overlapping claims and active enforcement.
- Alternative glycoengineering methods or entirely different protein modifications could avoid infringement.
- Patent expiration in 2030 presents opportunities for biosimilar entry, provided patent challenges are resolved.
FAQs
1. What proteins are covered under US Patent 8,267,903?
Modified erythropoietin molecules with specific glycosylation patterns intended to improve pharmacokinetics.
2. Can I produce EPO with different glycosylation patterns without infringing?
Claims are limited to specific glycan structures; producing variants outside these parameters may avoid infringement, subject to patent validity.
3. Are there licensing options for this patent?
Yes, licensing agreements may be negotiated with Amgen or their sublicensees, especially for commercial manufacturing.
4. How does this patent relate to biosimilar development?
It sets a baseline for modified EPO glycoforms, but biosimilar developers may design around by altering glycosylation or using different production methods.
5. When does this patent expire?
The patent expires on September 18, 2030, unless extended via regulatory exclusivities or legal challenges.
Citations
[1] U.S. Patent 8,267,903.
[2] Related patents: 7,899,279; 8,642,123; 7,619,001.
